We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 00:26:37 |
From Oct 2023 to Apr 2024
By Colin Kellaher
Merck & Co. has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.
Merck on Monday said it will pay $23 a share in cash for Harpoon, more than double Friday's closing price of $10.55 for the South San Francisco, Calif., company.
Bloomberg earlier reported that Rahway, N.J.-based Merck was in talks to buy Harpoon.
Merck said the deal adds Harpoon's HPN328, which is being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.
Merck, which is girding for the pending 2028 loss of patent protection for its blockbuster cancer drug Keytruda, said it expects to complete the Harpoon acquisition in the first half of the year, adding that the deal will result in a charge of about $650 million, or 26 cents a share.
Harpoon shares were recently up about 110% to $22.11 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 08, 2024 07:57 ET (12:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
